Approval · Notice of Compliance 2555 · 2001
EXELON: Notice of Compliance 2555
Issued April 4, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2555
- Date
- April 4, 2001
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product monograph update
- Therapeutic class
- Cholinesterase inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EXELON | Not yet assigned | — |
Medicinal ingredients
- RIVASTIGMINE HYDROGEN TARTRATE 1.5 MG per CAP
- RIVASTIGMINE HYDROGEN TARTRATE 3 MG per CAP
- RIVASTIGMINE HYDROGEN TARTRATE 4.5 MG per CAP
- RIVASTIGMINE HYDROGEN TARTRATE 6 MG per CAP